A Decade of Experience With Continuous-Flow Left Ventricular Assist Devices

Area of Science:

• Cardiology
• Biomedical Engineering
• Medical Devices

Background:

• Continuous-flow left ventricular assist devices (CF-LVADs) represent a significant advancement in mechanical circulatory support for advanced heart failure.
• The HeartMate II (HM II) is a widely used current-generation CF-LVAD.

Purpose of the Study:

• To review the long-term clinical experience with the HeartMate II CF-LVAD.
• To analyze survival rates and secondary outcomes in patients receiving HM II support over a decade.

Main Methods:

• Retrospective analysis of 267 patients who received HM II implantation between June 2005 and June 2014.
• Patients were divided into three equal groups based on implantation time period for comparative analysis.
• Time-to-event analysis (Kaplan-Meier) and one-way ANOVA were used to assess survival and secondary outcomes.

Main Results:

• Overall survival rates at 1, 2, 3, 4, and 5 years were 77%, 65%, 60%, 50%, and 48%, respectively.
• Patients implanted from June 2009 onwards (Groups 2 and 3) demonstrated improved survival rates compared to the earlier group (Group 1) (P=0.003).
• Later periods showed increased use of HM II for destination therapy, reduced driveline infections, and increased hemolysis.

Conclusions:

• The HeartMate II has positively impacted outcomes for end-stage heart failure patients.
• Major complications associated with HM II therapy continue to limit long-term survival.
• Future advancements in pump-host compatibility, anticoagulation, and fully implantable devices are needed to further improve outcomes and establish CF-LVADs as a long-term alternative to heart transplantation.